Literature DB >> 20110571

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

Estelle Nobécourt1, Fatiha Tabet, Gilles Lambert, Rajesh Puranik, Shisan Bao, Ling Yan, Michael J Davies, Bronwyn E Brown, Alicia J Jenkins, Gregory J Dusting, David J Bonnet, Linda K Curtiss, Philip J Barter, Kerry-Anne Rye.   

Abstract

OBJECTIVE: The goal of this study was to investigate the effects of nonenzymatic glycation on the antiinflammatory properties of apolipoprotein (apo) A-I. METHODS AND
RESULTS: Rabbits were infused with saline, lipid-free apoA-I from normal subjects (apoA-I(N)), lipid-free apoA-I nonenzymatically glycated by incubation with methylglyoxal (apoA-I(Glyc in vitro)), nonenzymatically glycated lipid-free apoA-I from subjects with diabetes (apoA-I(Glyc in vivo)), discoidal reconstituted high-density lipoproteins (rHDL) containing phosphatidylcholine and apoA-I(N), (A-I(N))rHDL, or apoA-I(Glyc in vitro), (A-I(Glyc in vitro))rHDL. At 24 hours postinfusion, acute vascular inflammation was induced by inserting a nonocclusive, periarterial carotid collar. The animals were euthanized 24 hours after the insertion of the collar. The collars caused intima/media neutrophil infiltration and increased endothelial expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1). ApoA-I(N) infusion decreased neutrophil infiltration and VCAM-1 and ICAM-1 expression by 89%, 90%, and 66%, respectively. The apoA-I(Glyc in vitro) infusion decreased neutrophil infiltration by 53% but did not reduce VCAM-1 or ICAM-1 expression. ApoA-I(Glyc in vivo) did not inhibit neutrophil infiltration or adhesion molecule expression. (A-I(Glyc in vitro))rHDL also inhibited vascular inflammation less effectively than (A-I(N))rHDL. The reduced antiinflammatory properties of nonenzymatically glycated apoA-I were attributed to a reduced ability to inhibit nuclear factor-kappaB activation and reactive oxygen species formation.
CONCLUSIONS: Nonenzymatic glycation impairs the antiinflammatory properties of apoA-I.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20110571      PMCID: PMC3038672          DOI: 10.1161/ATVBAHA.109.201715

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  33 in total

1.  Biochemistry and molecular cell biology of diabetic complications.

Authors:  M Brownlee
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

Review 2.  Regulation of intercellular adhesion molecule-1 (CD54) gene expression.

Authors:  K A Roebuck; A Finnegan
Journal:  J Leukoc Biol       Date:  1999-12       Impact factor: 4.962

3.  Glycated apolipoprotein A-I assay by combination of affinity chromatography and latex immunoagglutination.

Authors:  K Shishino; M Murase; H Makino; S Saheki
Journal:  Ann Clin Biochem       Date:  2000-07       Impact factor: 2.057

4.  N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression.

Authors:  T Kislinger; C Fu; B Huber; W Qu; A Taguchi; S Du Yan; M Hofmann; S F Yan; M Pischetsrieder; D Stern; A M Schmidt
Journal:  J Biol Chem       Date:  1999-10-29       Impact factor: 5.157

5.  Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation.

Authors:  G W Cockerill; T Y Huehns; A Weerasinghe; C Stocker; P G Lerch; N E Miller; D O Haskard
Journal:  Circulation       Date:  2001-01-02       Impact factor: 29.690

6.  Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia.

Authors:  R Marfella; K Esposito; R Giunta; G Coppola; L De Angelis; B Farzati; G Paolisso; D Giugliano
Journal:  Circulation       Date:  2000-05-16       Impact factor: 29.690

7.  Activation of NF-kappa B via the Ikappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells.

Authors:  A Denk; M Goebeler; S Schmid; I Berberich; O Ritz; D Lindemann; S Ludwig; T Wirth
Journal:  J Biol Chem       Date:  2001-05-03       Impact factor: 5.157

8.  Glycation impairs high-density lipoprotein function.

Authors:  C C Hedrick; S R Thorpe; M X Fu; C M Harper; J Yoo; S M Kim; H Wong; A L Peters
Journal:  Diabetologia       Date:  2000-03       Impact factor: 10.122

9.  The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro.

Authors:  Fatiha Tabet; Alan T Remaley; Aude I Segaliny; Jonathan Millet; Ling Yan; Shirley Nakhla; Philip J Barter; Kerry-Anne Rye; Gilles Lambert
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-12-03       Impact factor: 8.311

10.  Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells.

Authors:  P W Baker; K A Rye; J R Gamble; M A Vadas; P J Barter
Journal:  J Lipid Res       Date:  1999-02       Impact factor: 5.922

View more
  47 in total

1.  Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals.

Authors:  Michal Schnaider Beeri; Erin Moshier; James Schmeidler; James Godbold; Jaime Uribarri; Sarah Reddy; Mary Sano; Hillel T Grossman; Weijing Cai; Helen Vlassara; Jeremy M Silverman
Journal:  Mech Ageing Dev       Date:  2011-11-03       Impact factor: 5.432

Review 2.  High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease.

Authors:  Meliana Riwanto; Ulf Landmesser
Journal:  J Lipid Res       Date:  2013-07-20       Impact factor: 5.922

3.  Abnormal glucose and lipid control in non-ischemic left ventricular dysfunction.

Authors:  Danilo Neglia; Tiziana Sampietro; Cecilia Vecoli; Riccardo Liga; Giuseppe Rossi; Elena Filidei; Federico Bigazzi; Patricia Iozzo; Daniela Giannessi; Antonio L'Abbate; Daniele Rovai
Journal:  J Nucl Cardiol       Date:  2012-08-10       Impact factor: 5.952

Review 4.  HDL and cholesterol: life after the divorce?

Authors:  Kasey C Vickers; Alan T Remaley
Journal:  J Lipid Res       Date:  2013-03-19       Impact factor: 5.922

Review 5.  Niacin: another look at an underutilized lipid-lowering medication.

Authors:  Julia C Creider; Robert A Hegele; Tisha R Joy
Journal:  Nat Rev Endocrinol       Date:  2012-02-21       Impact factor: 43.330

Review 6.  Novel biological functions of high-density lipoprotein cholesterol.

Authors:  Chieko Mineo; Philip W Shaul
Journal:  Circ Res       Date:  2012-09-28       Impact factor: 17.367

Review 7.  Biomarkers associated with high-density lipoproteins in atherosclerotic kidney disease.

Authors:  Kerry-Anne Rye
Journal:  Clin Exp Nephrol       Date:  2013-09-20       Impact factor: 2.801

Review 8.  Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease.

Authors:  Rai Ajit K Srivastava
Journal:  Mol Cell Biochem       Date:  2017-08-21       Impact factor: 3.396

Review 9.  HDL dysfunction in diabetes: causes and possible treatments.

Authors:  Dan Farbstein; Andrew P Levy
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-03

10.  Semiquantitative analysis of apolipoprotein A-I modified by advanced glycation end products in diabetes mellitus.

Authors:  Yoshifumi Kurosaki; Tomoaki Tsukushi; Shinichi Munekata; Tohru Akahoshi; Tatsumi Moriya; Zensuke Ogawa
Journal:  J Clin Lab Anal       Date:  2013-02-25       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.